drugset
Drugs / ccIIV4
last change May 2024 re-read 3 minutes ago

ccIIV4

also known as quadrivalent cell culture-based influenza vaccine

Vaccine

Developed for
COVID-19 · influenza · asthma
Investigated by
Arizona State University · Centers for Disease Control and Prevention · Cleveland VA Medical Center · Duke University · Senders Pediatrics · University Hospitals Cleveland Medical Center
+3 more · University of Pittsburgh · Valleywise Health · Washington University School of Medicine

Trials 1

today NCT06020118 · Ph 4
202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 41 trial · 1 missed
Phase 4 NCT06020118 Sep 2023 → Mar 2024 COVID-19, influenza Duke University Completed Missed primary
Comparator or background therapy1 trial
Phase 4 NCT02967393 Comparator Oct 2016 → Feb 2017 asthma Vanderbilt University Medical Center Completed No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as ccIIV4 “approved quadrivalent cell culture-based influenza vaccine (ccIIV4, Seqirus)” NCT06020118 ↗
1

NCT02967393 ↗
Known as quadrivalent cell culture-based influenza vaccine “an approved quadrivalent cell culture-based influenza vaccine (ccIIV4, Seqirus)” NCT06020118 ↗
Modality Vaccine “cell cultured quadrivalent inactivated influenza vaccine (ccIIV4)(Flucelvax®) being used as a surrogate for LAIV4” NCT02967393 ↗
Route Intramuscular “0.5 mL intramuscular injection” NCT02967393 ↗